Joanna Horobin
Known title: DirectorCIK: 0001560959
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.
Transaction History
| LQDA | ▲ Buy | Grant | 5,882 | $0 | 6/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 5,000 | $136K | 8/19/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 18,396 | $0 | 6/17/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 20,359 | $0 | 6/20/2024 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 8,500 | $18K | 6/7/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 6,313 | $209K | 6/7/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,187 | $71K | 6/7/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.